Akoya Biosciences, Inc.
NasdaqGS:AKYA Lagerbericht
Marktkapitalisierung: US$156.9m
Akoya Biosciences Ausschüttungen und Rückkäufe
Zukünftiges Wachstum Kriterienprüfungen 0/6 Akoya Biosciences hat in der Vergangenheit keine Dividende gezahlt.
Wichtige Informationen
n/a
Dividendenausschüttung
Gesamte Aktionärsrendite 0.07% Zukünftige Dividendenrendite 0% Wachstum der Dividende n/a Nächster Dividendenzahlungstermin n/a Ex-Dividendendatum n/a Dividende pro Aktie n/a Ausschüttungsquote n/a
Jüngste Updates zu Dividenden und Rückkäufen
Alle Updates anzeigen
Is Akoya Biosciences (NASDAQ:AKYA) Using Too Much Debt? Nov 12
Precision for Medicine to Offer Spatial Biology Solutions Incorporating the PhenoCycler-Fusion 2.0 System and the new Phenocode Discovery IO60 Panel from Akoya Biosciences Nov 07
Akoya Biosciences, Inc. to Report Q3, 2024 Results on Nov 14, 2024 Oct 28
Akoya Biosciences, Inc. (NASDAQ:AKYA) Stock Rockets 36% But Many Are Still Ignoring The Company Oct 08
Akoya Biosciences, Inc. Announces Board Changes Oct 04
Akoya Biosciences, Inc. (NASDAQ:AKYA) Just Reported, And Analysts Assigned A US$5.42 Price Target Aug 09
Second quarter 2024 earnings: EPS in line with expectations, revenues disappoint Aug 06
Akoya Biosciences, Inc. Updates Earnings Guidance for the Full Year of 2024 Aug 06
New major risk - Share price stability Aug 04
Akoya Biosciences, Inc. to Report Q2, 2024 Results on Aug 05, 2024 Jul 16
Market Might Still Lack Some Conviction On Akoya Biosciences, Inc. (NASDAQ:AKYA) Even After 31% Share Price Boost Jun 27
Is Akoya Biosciences (NASDAQ:AKYA) A Risky Investment? Jun 24
We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Akoya Biosciences, Inc.'s (NASDAQ:AKYA) CEO For Now May 29
Consensus EPS estimates fall by 31% May 21
Akoya Biosciences, Inc. Provides Revenue Guidance for the Full Year 2024 May 15
Price target decreased by 11% to US$8.17 May 14
Investors Continue Waiting On Sidelines For Akoya Biosciences, Inc. (NASDAQ:AKYA) May 10
Akoya Biosciences and Shanghai KR Pharmtech Announces Chinese Regulatory Agency Premarket Approval for KR-HT5 in China to Support Next Generation Pathology Clinical Workflows May 03
Akoya Biosciences, Inc., Annual General Meeting, Jun 04, 2024 Apr 24
Akoya Biosciences, Inc. to Report Q1, 2024 Results on May 13, 2024 Apr 23
Akoya Biosciences Showcases Spatial Biology 2.0 Solutions At AACR Annual Meeting with Case Studies Demonstrating Unprecedented Speed and Scale Apr 05
Consensus EPS estimates upgraded to US$0.83 loss Mar 12
Full year 2023 earnings: EPS exceeds analyst expectations Mar 05
Is Akoya Biosciences (NASDAQ:AKYA) Weighed On By Its Debt Load? Feb 28
Akoya Biosciences, Inc. to Report Q4, 2023 Results on Mar 04, 2024 Feb 09
High number of new directors Feb 01
Akoya Biosciences Deploys the Maxfuse Algorithm Co-Developed by Dr. Garry Nolan and His Laboratory At Stanford University for Multiomic Integration of Spatial and Single-Cell Data on the Enable Medicine Platform Jan 09
Akoya Biosciences, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2023 and for the Fiscal Year 2024 Jan 08
Price target decreased by 11% to US$9.25 Dec 19
Investors Still Aren't Entirely Convinced By Akoya Biosciences, Inc.'s (NASDAQ:AKYA) Revenues Despite 31% Price Jump Nov 25
Consensus EPS estimates upgraded to US$1.46 loss Nov 16
New minor risk - Share price stability Nov 15
Price target decreased by 8.3% to US$11.00 Nov 12
Akoya Biosciences, Inc. Reiterates Revenue Guidance for the Fiscal Year 2023 Nov 10
Third quarter 2023 earnings: EPS and revenues exceed analyst expectations Nov 10
Akoya Biosciences to Showcase New Spatial Biology 2.0 Solutions and Spatial Phenotyping Data at SITC 2023 Nov 01
Price target decreased by 7.1% to US$13.13 Oct 17
Akoya Biosciences, Inc. to Report Q3, 2023 Results on Nov 08, 2023 Oct 12
Akoya Biosciences, Inc. Launches PhenoCycler-Fusion 2.0 and Phenoimager HT 2.0 Platform Upgrades Sep 20
Chief Operating Officer recently bought US$92k worth of stock Sep 12
Akoya Biosciences, Inc. Provides Revenue Guidance for the Fiscal Year 2023 Aug 09
Price target decreased by 12% to US$14.14 Aug 08
Akoya Biosciences, Inc. to Report Q2, 2023 Results on Aug 07, 2023 Jul 13
Price target decreased by 8.6% to US$16.00 Jul 10
New minor risk - Share price stability Jun 14 Akoya Biosciences, Inc. has completed a Follow-on Equity Offering in the amount of $43.5 million. Jun 10
Akoya Biosciences, Inc. has completed a Follow-on Equity Offering in the amount of $43.5 million. Jun 09
Akoya Biosciences, Inc. Announces Executive Changes Jun 08
First quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat May 10
Akoya Biosciences, Inc. Provides Revenue Guidance for the Full Year 2023 May 09
Price target decreased by 7.9% to US$17.50 Apr 21
Consensus EPS estimates fall by 11%, revenue upgraded Mar 15
Full year 2022 earnings: EPS misses analyst expectations Mar 08
Akoya Biosciences, Inc. to Report Q4, 2022 Results on Mar 06, 2023 Feb 07
Akoya Biosciences, Inc. to Present First-of-its-Kind Spatial Multiomics Dataset at 2023 AGBT General Meeting Feb 02
Akoya Biosciences, Inc. Provides Revenue Guidance for the Fourth Quarter and Fiscal Year 2022 Jan 09
Chief Financial Officer exercised options to buy US$2.2m worth of stock. Dec 28
Chief Financial Officer exercised options and sold US$298k worth of stock Dec 18
President exercised options and sold US$59k worth of stock Dec 09
Co-Founder recently sold US$67k worth of stock Dec 03
Co-Founder notifies of intention to sell stock Nov 18
Co-Founder recently sold US$325k worth of stock Nov 16
Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind Nov 09 Akoya Biosciences, Inc Launches PhenoCode Signature Panels to Accelerate Development of Predictive Biomarkers for Cancer Immunotherapy
Akoya Biosciences, Inc. to Report Q3, 2022 Results on Nov 07, 2022 Oct 12
Co-Founder recently sold US$319k worth of stock Sep 14
President exercised options and sold US$63k worth of stock Sep 10
Price target increased to US$20.40 Aug 22
Consensus forecasts updated Aug 16
Akoya Biosciences, Inc. Raises Earnings Guidance for the Full Year 2022 Aug 09
Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind Aug 09
Akoya Biosciences, Inc. to Report Q2, 2022 Results on Aug 08, 2022 Jul 13
Price target decreased to US$18.60 Jun 22
President notifies of intention to sell stock Jun 19
Akoya Biosciences Seeks Growth Despite Higher Operating Losses May 30
Consensus forecasts updated May 13
Akoya Biosciences, Inc. (NASDAQ:AKYA) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock? May 11
First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind May 06
Akoya Biosciences, Inc. Revises Revenue Guidance for the Full Year of 2022 May 06
Price target decreased to US$20.50 Apr 27
Akoya Biosciences, Inc., Annual General Meeting, Jun 01, 2022 Apr 22
Akoya Biosciences Announces Ehab A. El-Gabry, MD, as Chief Medical Officer Apr 20
Chief Business Officer exercised options to buy US$844k worth of stock. Apr 15
Akoya Biosciences, Inc. to Report Q1, 2022 Results on May 05, 2022 Apr 15
Consensus forecasts updated Mar 22
Full year 2021 earnings: EPS misses analyst expectations Mar 15
Akoya Biosciences, Inc. to Report Q4, 2021 Results on Mar 14, 2022 Feb 24
Akoya Biosciences Announces Commercial Launch of PhenoCycler-Fusion, the Faster Single-Cell Spatial Biology System Jan 14
Akoya Biosciences, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2021 Jan 12
Consensus forecasts updated Jan 12
Akoya Biosciences, Inc. Unveils Comprehensive Roadmap of Innovations at Inaugural Spatial Day Event Dec 16
Co-Founder recently sold US$317k worth of stock Dec 14
Co-Founder notifies of intention to sell stock Dec 14
Chairman of the Board recently bought US$441k worth of stock Nov 20
Stabilität und Wachstum des Zahlungsverkehrs
Stabile Dividende: Es liegen keine ausreichenden Daten vor, um festzustellen, ob die Dividende je Aktie von AKYA in der Vergangenheit stabil war.
Wachsende Dividende: Unzureichende Daten, um festzustellen, ob die Dividendenzahlungen von AKYA gestiegen sind.
Dividendenrendite im Vergleich zum Markt Akoya Biosciences Dividendenrendite im Vergleich zum Markt
Wie sieht die Dividendenrendite von AKYA im Vergleich zum Markt aus? Segment Dividendenrendite Unternehmen (AKYA) n/a Untere 25 % des Marktes (US) 1.3% Markt Top 25 % (US) 4.3% Branchendurchschnitt (Life Sciences) 0.5% Analystenprognose (AKYA) (bis zu 3 Jahre) 0%
Bemerkenswerte Dividende: Es ist nicht möglich, die Dividendenrendite von AKYA im Vergleich zu den unteren 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.
Hohe Dividende: Es ist nicht möglich, die Dividendenrendite von AKYA im Vergleich zu den besten 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.
Gewinnausschüttung an die Aktionäre
Abdeckung der Erträge: Unzureichende Daten zur Berechnung der Ausschüttungsquote von AKYA, um festzustellen, ob die Dividendenzahlungen durch die Gewinne gedeckt sind.
Barausschüttung an die Aktionäre
Cashflow-Deckung: Es ist nicht möglich, die Nachhaltigkeit der Dividende zu berechnen, da AKYA keine Ausschüttungen gemeldet hat.
Entdecken Sie dividendenstarke Unternehmen Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
